Pediatric Tumor Cells Express Erythropoietin and a Functional Erythropoietin Receptor that Promotes Angiogenesis and Tumor Cell Survival

Laboratory Investigation

Volumn 83, Issue 10, 2003, Pages 1477-1487

  Batra, Sandeep ^a,b   Perelman, Natalya ^a,b   Luck, Lori R ^a,b   Shimada, Hiroyuki ^a,b   Malik, Punam ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CELL NUCLEUS DNA; CELL PROTEIN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACENTAL GROWTH FACTOR; PROTEIN BCL 1; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER CELL CULTURE; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; EPENDYMOMA; EWING SARCOMA; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HEPATOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; NEPHROBLASTOMA; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR CELL; UPREGULATION;

CELL HYPOXIA; CELL SURVIVAL; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL GROWTH FACTORS; ERYTHROPOIETIN; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0142043003     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000090156.94795.48     Document Type: Article

References (49)

1. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, and Verma A (2001). Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561-3565.
2. Acs G, Zhang PJ, Rebbeck TR, Acs P, and Verma A (2002). Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95:969-981.
3. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, and Haroon ZA (2002). Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82:911-918.
4. Bittorf T, Buchse T, Sasse T, Jaster R, and Brock J (2001). Activation of the transcription factor NF-kappaB by the erythropoietin receptor: Structural requirements and biological significance. Cell Signal 13:673-681.
5. Blancher C, Moore JW, Talks KL, Houlbrook S, and Harris AL (2000). Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60:7106-7113.
6. Bunn HF, Gu J, Huang LE, Park JW, and Zhu H (1998). Erythropoietin: A model system for studying oxygen-dependent gene regulation. J Exp Biol 201:1197-1201.
7. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M, and Bellorin-Font E (1999). Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546-553.
8. Digicaylioglu M and Lipton SA (2001). Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412:641-647.
9. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, and Gassmann M (1995). Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 92:3717-3720.
10. Dillard DG, Venkatraman G, Cohen C, Delgaudio J, Gal AA, and Mattox DE (2001). Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol 121:149-152.
11. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, and Semenza GL (2002). IGF-1 induces HIF-1-mediated VEGF expression that is dependent on MAP kinase and PI-3-kinase signaling in colon cancer cells. J Biol Chem 277:38205-38211.
12. Gleadle JM, Ebert BL, Firth JD, and Ratcliffe PJ (1995). Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol 268:C1362-C1368.
13. Goldberg MA, Glass GA, Cunningham JM, and Bunn HF (1987). The regulated expression of erythropoietin by two human hepatoma cell lines. Proc Natl Acad Sci USA 84:7972-7976.
14. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, and Brines M (2002). Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99:9450-9455.
15. Green CJ, Lichtlen P, Huynh NT, Yanovsky M, Laderoute KR, Schaffner W, and Murphy BJ (2001). Placenta growth factor gene expression is induced by hypoxia in fibroblasts: A central role for metal transcription factor-1. Cancer Res 61:2696-2703.
16. Gregory T, Yu C, Ma A, Orkin SH, Blobel GA, and Weiss MJ (1999). GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 94:87-96.
17. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, Bauer C, Gassmann M, and Reme CE (2002). HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 8:718-724.
18. Hansgen G, Hintner I, Krause V, Wohlrab W, and Dunst J (1997). Intratumor pO2, S-phase fraction and p53 status in cervix carcinomas. Strahlenther Onkol 173:385-387.
19. Harris AL (2002). Hypoxia: A key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
20. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, and Rosenbaum DM (2002). Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 99:10659-10664.
21. Juul SE (2000). Nonerythropoietic roles of erythropoietin in the fetus and neonate. Clin Perinatol 27:527-541.
22. Juul SE, Yachnis AT, and Christensen RD (1998). Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235-249.
23. Juul SE, Yachnis AT, Rojiani AM, and Christensen RD (1999). Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 2:148-158.
24. Linet MS, Ries LA, Smith MA, Tarone RE, and Devesa SS (1999). Cancer surveillance series: Recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 91:1051-1058.
25. Liu ZY, Chin K, and Noguchi CT (1994). Tissue specific expression of human erythropoietin receptor in transgenic mice. Dev Biol 166:159-169.
26. Lu R, Au WC, Yeow WS, Hageman N, and Pitha PM (2000). Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem 275:31805-31812.
27. Malik P, Krall WJ, Yu X-J, Zhou C, and Kohn DB (1995). Retroviral mediated gene expression in human myelomonocytic cells: A comparison of hematopoietic cell promoters to viral promoters. Blood 86:2993-3005.
28. Marti HH, Wenger RH, Rivas LA, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, and Gassmann M (1996). Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8:666-676.
29. Moreau-Gaudry F, Xia P, Jiang G, Perelman NP, Bauer G, Ellis J, Surinya KH, Mavilio F, Shen CK, and Malik P (2001). High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 98:2664-2672.
30. Murphy GP, Mirand EA, and Staubitz WJ (1976). The value of erythropoietin assay in the follow-up of Wilms' tumor patients. Oncology 33:154-156.
31. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, and Kim SU (2001). Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386-392.
32. Nitta K, Uchida K, Kimata N, Honda K, Kobayashi H, Kawashima A, Yumura W, and Nihei H (1999). Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells. Eur J Pharmacol 373:121-124.
33. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, and Noguchi CT (2000). Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275:39754-39761.
34. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstien A, Coates TD, Kalra VK, and Malik P (2003). Placenta growth factor is increased in sickle cell disease, activates monocytes and modulates the clinical severity of sickle cell disease. Blood 102:1506-1514.
35. Ribatti D (2002). A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes. Leukemia 16:1890.
36. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, and Dammacco F (1999). Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627-2636.
37. Sakisaka S, Watanabe M, Tateishi H, Harada M, Shakado S, Mimura Y, Gondo K, Yoshitake M, Noguchi K, Hino T, et al (1993). Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology 18:1357-1362.
38. Semenza GL (2002). Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 41:79-83.
39. Shimonaka M and Yamaguchi Y (1994). Purification and biological characterization of epitaxin: A fibroblast-derived motility factor for epithelial cells. J Biol Chem 269:14284-14289.
40. Spivak JL, Ferris DK, Fisher J, Noga SJ, Isaacs M, Connor E, and Hankins WD (1996). Cell cycle-specific behavior of erythropoietin. Exp Hematol 24:141-150.
41. Stolze I, Berchner-Pfannschmidt U, Freitag P, Wotzlaw C, Rossler J, Frede S, Acker H, and Fandrey J (2002). Hypoxia-inducible erythropoietin gene expression in human neuroblastoma cells. Blood 100:2623-2628.
42. Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, and Asou H (2002). Effects of erythropoietin on glial cell development: Oligodendrocyte maturation and astrocyte proliferation. Neurosci Res 44:391-403.
43. Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, and Yamamoto M (2002). Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 100:2279-2288.
44. Thurman WG, Grabstald H, and Lieberman PH (1966). Elevation of erythropoietin levels in association with Wilms' tumor. Arch Intern Med 117:280-283.
45. Vaupel P, Kelleher DK, and Hockel M (2001). Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28:29-35.
46. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, and Sasaki R (1998). Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273:25381-25387.
47. Yasuda Y, Musha T, Tanaka H, Fujita Y, Fujita H, Utsumi H, Matsuo T, Masuda S, Nagao M, Sasaki R, and Nakamura Y (2001). Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer 84:836-843.
48. Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B, Lin CS, Nikodem VM, Hempstead B, Flanders KC, Costantini F, and Noguchi CT (2002). Erythropoietin receptor signalling is required for normal brain development. Development 129:505-516.
49. Zhu H and Bunn HF (2001). Signal transduction. How do cells sense oxygen? Science 292:449-451.